Mayo Clinic Talks COVID-19 Miniseries Episode 36: A Comprehensive Update on COVID-19

Mayo Clinic Talks

Mayo Clinic Talks Podcast #171

COVID-19 Miniseries Episode 36: A Comprehensive Update on COVID-19

Registration required for CME credit

 

Listen on Apple Podcast  Listen on Google Play Music  Listen on Spotify

You can also listen through your favorite podcast platform:
Apple Podcasts | Google Play Music | Stitcher | Spotify


COVID-19 information evolves daily.  The views and perspectives shared in these resources are presented based on information available at the time of recording.
Recorded June, 2020

For the most up to date information visit:
CDC - Information for Healthcare Professionals about Coronavirus (COVID-19)
World Health Organization's Country & Technical Guidance - Coronavirus disease (COVID-19)
AskMayoExpert COVID-19 Navigator
COVID-19 Online Education, Resources and Updates

Guest: Raymund R. Razonable, M.D.
@Razonablemd

Host: Amit K. Ghosh, M.D., M.B.A.
@amitghosh006


Up to about 50% of people infected with SARS-CoV-2 are asymptomatic spreaders. About 80% of those who are symptomatic, developing COVID-19, have mild disease displaying dry cough, fever, and fatigue. The resulting 20% of symptomatic patients accounts for those who develop progressive respiratory distress and sometimes multi-organ failure, among other complications. We’re learning more about anosmia, cardiac injury, and “COVID-toes.” What’s known about COVID-19 and SARS-CoV-2 continues to evolve. Dr. Raymund Razonable walks through a recently published update on the management of COVID-19. 

Time Stamps:
1:18 - New signs and symptoms of COVID-19.
3:30 - Testing characteristics (sensitivity, specificity, and indications)  of the molecular and serologic testing for SARS-CoV-2
6:22 - Risk factors and the prediction of disease progression for patients hospitalized with COVID-19
9:28 - Hyper-inflammatory syndrome and progression to multi-system organ failure syndrome
10:45 - Multisystem inflammatory syndrome in children (MIS-C)
11:22 - Cardiac complications - 3 factors
12:50 - Diagnosis and treatment of co-infection in hospitalized patients (COVID-19 and flu, COVID-19 and pneumonia)
16:31 - Evidence-based treatment based on the 3 phases of COVID-19 viremic phase, pneumonic phase, hyperinflammation phase
18:06 - Remdesivir update
21:00 - Hydroxychloroquine update
23:25 - Favipiravir and lopinavir-ritonavir update
23:53 - Treatment of the hyperinflammatory phase (sarilumab, tocilizumab, lenzilumab, anakinra,)
27:13 - Convalescent plasma
28:04 - Discharge and social determinants of health
33:40 - Telehealth and remote monitoring
35:40 - Health disparities and telehealth
37:47 - What’s the next development Infectious Disease specialists are looking for in relation to the COVID-19 pandemic?

See the article here:
A Collaborative Multidisciplinary Approach to the Management of Coronavirus Disease-19 in the Hospital Setting https://doi.org/10.1016/j.mayocp.2020.05.01

 

Target Audience

This course is intended for primary care providers: physicians, nurse practitioners, and physician assistants

Learning Objectives

Upon completion of the Mayo Clinic Talks Podcast course, learners should be able to:

  • Describe the current treatment recommendations for patients with hyperlipidemia.
  • List the various categories of hypertension.
  • Describe the current pharmacologic treatment available for patients with osteoporosis.

Participation in this Mayo Clinic online course does not indicate nor guarantee competence or proficiency in the performance of any procedures which may be discussed or taught in this course.

Course summary
Available credit: 
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Attendance
Course opens: 
06/08/2020
Course expires: 
12/29/2022
Cost:
$10.00
Part of: 
Mayo Clinic Talks Podcast: COVID-19 Miniseries

Accreditation Statement
In support of improving patient care, Mayo Clinic College of Medicine and Science is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Credit Statement(s):

AMA

Mayo Clinic College of Medicine and Science designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For disclosure information regarding Mayo Clinic School of Continuous Professional Development accreditation review committee member(s), please go here to review disclosures.

Available Credit

  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Attendance

Price

Cost:
$10.00
Please login or register to take this course.

Thank you for joining us!  

Everything you need to complete this course is listed in the Course Progress column on this page's left-hand side.  This handy checklist has all of the course components needing completion.  Do them in any order, but completion of all is required for credit.
 

For cancellation details, contact cme@mayo.edu